Abstract
Powering cancer screening for overall mortality.
Highlights
From the point of view of federal agencies charged with dispersing a set pool of research funds, such as the National Institutes of Health, spending so much money on any single trial inherently comes at the price of forgoing many other pressing studies
One screening prevention mega-trial may cost as much as 50 well-done randomized trials for patients with metastatic cancer
The cascade of events it prompts, costs taxpayers tens of billions of dollars each year. While it remains controversial whether diagnosing many cancers at an earlier state results in savings from metastatic treatment averted, it is certain that the extent of over diagnosis in cancer screening ensures that substantial spending is wasted [5]
Summary
From the point of view of federal agencies charged with dispersing a set pool of research funds, such as the National Institutes of Health, spending so much money on any single trial inherently comes at the price of forgoing many other pressing studies. One screening prevention mega-trial may cost as much as 50 well-done randomized trials for patients with metastatic cancer. From a 30,000-foot viewpoint of the federal government, such a study could be a good buy.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
